ArticleRSC advances2021
Chitosan hydrogel for topical delivery of ebastine loaded solid lipid nanoparticles for alleviation of allergic contact dermatitis.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- DoE-oriented optimization of a chitosan-based nanoemulgel of clobetasol propionate for therapeutic intervention in psoriasis.RSC advances · 2026Article
- Papaya Peel Extract-Capped Copper Oxide Nanoparticle-Based Hydrogel: Enhanced Efficacy for Wound Healing.ACS omega · 2025Article
- Novel drug delivery systems in topical treatment of atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A drug delivery perspective on nanotechnology-based topical therapeutics for inflammatory skin diseases.Nanomedicine (London, England) · 2025Review
- Natural Matrine-Integrated Pollen Delivery Systems for Allergic Contact Dermatitis Treatment.Smart medicine · 2025Article
- Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles.International journal of nanomedicine · 2025Article
- Follicular mediated etodolac phosalosomal gel for contact dermatitis alleviation, insights from optimization to in-vivo appraisal.Scientific reports · 2024Article
- Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line.Nanomedicine (London, England) · 2024Article
- Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis.Pharmacological reports : PR · 2023Review
- Microemulsion-Based Keratin-Chitosan Gel for Improvement of Skin Permeation/Retention and Activity of Curcumin.Gels (Basel, Switzerland) · 2023Article
- New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective.ACS omega · 2023Review
- Chitosan-based drug delivery systems for skin atopic dermatitis: recent advancements and patent trends.Drug delivery and translational research · 2023Review
- Development andHeliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebastine, is an antihistamine drug that exerts its effect upon oral administration in humans for the treatment of allergic contact dermatitis (ACD), it also has some systemic side effects like gastric distress, headache, drowsiness, and epistaxis. Moreover, topical corticosteroids are used for treatment of ACD, which causes the human skin to lose its thickness and elasticity. Hence, ebastine-loaded solid lipid nanoparticles (E-SLNs) were prepared and their topical efficacy against allergic contact dermatitis was determined. Compritol 888 ATO and tween 80 were used to prepare E-SLNs by cold dilution of the hot micro-emulsion. E-SLNs were optimized statistically by employing a central composite design using Design-Expert® version 11.0. Optimized E-SLNs showed spherical surface morphology, zeta potential of -15.6 ± 2.4 mV, PDI of 0.256 ± 0.03, and particle sizes of 155.2 ± 1.5 nm and th eentrapment efficiency of ebastine was more than 78%. Nanoparticles were characterized using FT-IR, XRD, and TEM. An E-SLNs loaded hydrogel was prepared using chitosan as a gelling agent and glutaraldehyde as a crosslinker.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.